- Home
- TRUG vs NKGN Comparison
TRUG vs NKGN Comparison
Compare TRUG & NKGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRUG
- NKGN
- Stock Information
- Founded
- TRUG 1983
- NKGN 2017
- Country
- TRUG United States
- NKGN United States
- Employees
- TRUG N/A
- NKGN N/A
- Industry
- TRUG
- NKGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TRUG
- NKGN Health Care
- Exchange
- TRUG NYSE
- NKGN Nasdaq
- Market Cap
- TRUG 9.1M
- NKGN 14.1M
- IPO Year
- TRUG N/A
- NKGN N/A
- Fundamental
- Price
- TRUG $0.43
- NKGN $0.65
- Analyst Decision
- TRUG Strong Buy
- NKGN
- Analyst Count
- TRUG 1
- NKGN 0
- Target Price
- TRUG $2.00
- NKGN N/A
- AVG Volume (30 Days)
- TRUG 11.9M
- NKGN 573.1K
- Earning Date
- TRUG 02-12-2025
- NKGN 12-31-2024
- Dividend Yield
- TRUG N/A
- NKGN N/A
- EPS Growth
- TRUG N/A
- NKGN N/A
- EPS
- TRUG N/A
- NKGN N/A
- Revenue
- TRUG $21,917,131.00
- NKGN N/A
- Revenue This Year
- TRUG N/A
- NKGN N/A
- Revenue Next Year
- TRUG N/A
- NKGN N/A
- P/E Ratio
- TRUG N/A
- NKGN N/A
- Revenue Growth
- TRUG 7.68
- NKGN N/A
- 52 Week Low
- TRUG $0.35
- NKGN $0.20
- 52 Week High
- TRUG $11.82
- NKGN $4.06
- Technical
- Relative Strength Index (RSI)
- TRUG 44.87
- NKGN 65.93
- Support Level
- TRUG $0.35
- NKGN $0.45
- Resistance Level
- TRUG $0.92
- NKGN $0.62
- Average True Range (ATR)
- TRUG 0.11
- NKGN 0.08
- MACD
- TRUG 0.00
- NKGN 0.01
- Stochastic Oscillator
- TRUG 14.04
- NKGN 70.95
About TRUG TRUGOLF HOLDINGS INC
TruGolf Holdings Inc is a indoor golf gaming solutions company. It has built video games ("Links"), innovative hardware solutions, and an all-new e-sports platform to connect golfers around the world with E6 CONNECT.
About NKGN NKGen Biotech Inc.
NKGen Biotech Inc is a biotechnology company developing cell therapies for neurodegenerative and oncological diseases based on activated NK cells. NK cells are part of the human innate immune response system that can selectively identify and destroy abnormal or diseased cells. Its product candidates are based on a proprietary manufacturing and cryopreservation process that produces SuperNKTM (SNK) cells that have shown increased activity as compared to the starting population of NK cells, based on the results of in vitro experiments performed by NKMAX, as defined by parameters such as cytotoxicity, cytokine production and activating receptor expression. SNK cells can be produced in large quantities and cryopreserved while maintaining high levels of cytotoxicity.